S&P Futures
4,128.75 -13.00 (-0.31%) Dow Futures
32,758.00 -34.00 (-0.10%) Nasdaq Futures
13,101.50 -81.75 (-0.62%) Russell 2000 Futures
1,935.70 -5.40 (-0.28%) Crude Oil
91.76 +1.00 (+1.10%) Gold
1,806.10 +0.90 (+0.05%)
Cytokinetics, Incorporated (CYTK)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 51.82 |
| Open | 52.08 |
| Bid | 0.00 x 800 |
| Ask | 54.87 x 800 |
| Day's Range | 50.39 - 54.74 |
| 52 Week Range | 29.10 - 54.74 |
| Volume | |
| Avg. Volume | 1,386,803 |
| Market Cap | 4.518B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.11 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 62.75 |
- Benzinga
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M
Cytokinetics Inc (NASDAQ: CYTK) reported Q2 sales of $88.96 million compared to $2.84 million a year ago, primarily due to the recognition of $87 million deferred revenue for sales royalties of mavacamten as a result of the extinguishment of royalty obligations. The analysts estimated sales of $3.63 million. The company reported an EPS loss of $(0.23), down from $(0.86) a year ago. In June, the company received an FDA notice on plans to convene an Advisory Committee meeting to review the omecamt
- Zacks
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cytokinetics Reports Second Quarter 2022 Financial Results
Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quar
